Carrie Liao Sells 2,347 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CAO Carrie Liao sold 2,347 shares of Mind Medicine (MindMed) stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $15,818.78. Following the transaction, the chief accounting officer now directly owns 144,923 shares in the company, valued at approximately $976,781.02. The trade was a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Carrie Liao also recently made the following trade(s):

• On Thursday, December 26th, Carrie Liao sold 2,273 shares of Mind Medicine (MindMed) stock. The shares were sold at an average price of $7.43, for a total transaction of $16,888.39.

Mind Medicine (MindMed) Price Performance

MNMD opened at $6.43 on Friday. Mind Medicine has a 12-month low of $5.03 and a 12-month high of $12.22. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $484.62 million, a P/E ratio of -2.85 and a beta of 2.57. The stock has a fifty day moving average of $7.28 and a 200-day moving average of $6.95.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the previous year, the firm earned ($0.59) earnings per share. Equities analysts forecast that Mind Medicine will post -1.35 EPS for the current fiscal year.

Institutional Trading of Mind Medicine (MindMed)

Several institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC acquired a new stake in shares of Mind Medicine (MindMed) during the 3rd quarter valued at $134,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Mind Medicine (MindMed) by 8.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 602,544 shares of the company’s stock worth $3,428,000 after acquiring an additional 46,187 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Mind Medicine (MindMed) during the third quarter valued at $242,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Mind Medicine (MindMed) by 22.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,226 shares of the company’s stock valued at $126,000 after purchasing an additional 4,079 shares in the last quarter. Finally, State Street Corp increased its position in Mind Medicine (MindMed) by 0.5% in the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company’s stock worth $10,326,000 after purchasing an additional 9,782 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on MNMD shares. Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Chardan Capital assumed coverage on Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a “buy” rating and a $20.00 price objective for the company. Robert W. Baird decreased their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. Ten equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.